px-866 and Pulmonary-Fibrosis

px-866 has been researched along with Pulmonary-Fibrosis* in 2 studies

Other Studies

2 other study(ies) available for px-866 and Pulmonary-Fibrosis

ArticleYear
Dual targeting of MEK and PI3K pathways attenuates established and progressive pulmonary fibrosis.
    PloS one, 2014, Volume: 9, Issue:1

    Pulmonary fibrosis is often triggered by an epithelial injury resulting in the formation of fibrotic lesions in the lung, which progress to impair gas exchange and ultimately cause death. Recent clinical trials using drugs that target either inflammation or a specific molecule have failed, suggesting that multiple pathways and cellular processes need to be attenuated for effective reversal of established and progressive fibrosis. Although activation of MAPK and PI3K pathways have been detected in human fibrotic lung samples, the therapeutic benefits of in vivo modulation of the MAPK and PI3K pathways in combination are unknown. Overexpression of TGFα in the lung epithelium of transgenic mice results in the formation of fibrotic lesions similar to those found in human pulmonary fibrosis, and previous work from our group shows that inhibitors of either the MAPK or PI3K pathway can alter the progression of fibrosis. In this study, we sought to determine whether simultaneous inhibition of the MAPK and PI3K signaling pathways is a more effective therapeutic strategy for established and progressive pulmonary fibrosis. Our results showed that inhibiting both pathways had additive effects compared to inhibiting either pathway alone in reducing fibrotic burden, including reducing lung weight, pleural thickness, and total collagen in the lungs of TGFα mice. This study demonstrates that inhibiting MEK and PI3K in combination abolishes proliferative changes associated with fibrosis and myfibroblast accumulation and thus may serve as a therapeutic option in the treatment of human fibrotic lung disease where these pathways play a role.

    Topics: Analysis of Variance; Animals; Benzimidazoles; Blotting, Western; Drug Therapy, Combination; Gonanes; Immunohistochemistry; Lung; MAP Kinase Signaling System; Mice; Mice, Transgenic; Phosphoinositide-3 Kinase Inhibitors; Pulmonary Fibrosis; Real-Time Polymerase Chain Reaction; Sequence Analysis, RNA; Transforming Growth Factor alpha

2014
Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis.
    The American journal of pathology, 2010, Volume: 176, Issue:2

    Transforming growth factor-alpha (TGFalpha) is a ligand for the epidermal growth factor receptor (EGFR). EGFR activation is associated with fibroproliferative processes in human lung disease and animal models of pulmonary fibrosis. EGFR signaling activates several intracellular signaling pathways including phosphatidylinositol 3'-kinase (PI3K). We previously showed that induction of lung-specific TGFalpha expression in transgenic mice caused progressive pulmonary fibrosis over a 4-week period. The increase in levels of phosphorylated Akt, detected after 1 day of doxycycline-induced TGFalpha expression, was blocked by treatment with the PI3K inhibitor, PX-866. Daily administration of PX-866 during TGFalpha induction prevented increases in lung collagen and airway resistance as well as decreases in lung compliance. Treatment of mice with oral PX-866 4 weeks after the induction of TGFalpha prevented additional weight loss and further increases in total collagen, and attenuated changes in pulmonary mechanics. These data show that PI3K is activated in TGFalpha/EGFR-mediated pulmonary fibrosis and support further studies to determine the role of PI3K activation in human lung fibrotic disease, which could be amenable to targeted therapy.

    Topics: Administration, Oral; Animals; Disease Progression; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gonanes; Mice; Mice, Transgenic; Oncogene Protein v-akt; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pulmonary Fibrosis; Transforming Growth Factor alpha; Uteroglobin

2010